Vaxcyte (PCVX) Set to Release Quarterly Earnings on Tuesday

Vaxcyte (NASDAQ:PCVX) is expected to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of ($2.11) per share and revenue of $12.50 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:00 PM ET.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same period in the prior year, the firm posted ($1.22) EPS. On average, analysts expect Vaxcyte to post ($7.47) EPS for the current fiscal year and ($6.36) EPS for the next fiscal year.

Vaxcyte Stock Down 0.8%

Shares of NASDAQ PCVX opened at $59.97 on Tuesday. The business has a fifty day simple moving average of $61.53 and a 200-day simple moving average of $56.54. Vaxcyte has a 12 month low of $39.87 and a 12 month high of $90.75.

Analyst Ratings Changes

Several research firms recently weighed in on PCVX. Guggenheim upped their price target on Vaxcyte from $116.00 to $125.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Needham & Company LLC boosted their price target on shares of Vaxcyte from $110.00 to $122.00 and gave the company a “buy” rating in a report on Monday, October 5th. Wall Street Zen raised Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Bank of America reduced their price target on Vaxcyte from $133.00 to $130.00 and set a “buy” rating for the company in a report on Monday, September 28th. Finally, BTIG Research restated a “buy” rating and issued a $89.00 price objective on shares of Vaxcyte in a report on Monday, October 5th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.50.

Insider Activity

In other Vaxcyte news, EVP Jim Wassil sold 18,000 shares of the company’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $86.74, for a total transaction of $1,561,320.00. Following the completion of the sale, the executive vice president directly owned 145,435 shares in the company, valued at $12,615,031.90. This represents a 11.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $53.89, for a total value of $538,900.00. Following the completion of the sale, the chief financial officer directly owned 105,176 shares in the company, valued at approximately $5,667,934.64. This represents a 8.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 74,692 shares of company stock valued at $5,308,175 in the last quarter. 3.30% of the stock is currently owned by corporate insiders.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.